Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Gastric Cancer | Review

LncRNA MAFG-AS1 is involved in human cancer progression

Authors: Penghui Li, Xiao Ma, Xinyu Gu

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Long noncoding RNAs (lncRNAs) refer to a type of non-protein-coding transcript of more than 200 nucleotides. LncRNAs play fundamental roles in disease development and progression, and lncRNAs are dysregulated in many pathophysiological processes. Thus, lncRNAs may have potential value in clinical applications. The lncRNA, MAF BZIP Transcription Factor G (MAFG)-AS1, is dysregulated in several cancer, including breast cancer, lung cancer, liver cancer, bladder cancer, colorectal cancer, gastric cancer, esophagus cancer, prostate cancer, pancreatic cancer, ovarian cancer, and glioma. Altered MAFG-AS1 levels are also associated with diverse clinical characteristics and patient outcomes. Mechanistically, MAFG-AS1 mediates a variety of cellular processes via the regulation of target gene expression. Therefore, the diagnostic, prognostic, and therapeutic aspects of MAFG-AS1 have been widely explored. In this review, we discuss the expression, major roles, and molecular mechanisms of MAFG-AS1, the relationship between MAFG-AS1 and clinical features of diseases, and the clinical applications of MAFG-AS1.
Literature
1.
2.
Jogalekar MP, et al. CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Front Immunol. 2022;13: 925985.PubMedPubMedCentralCrossRef
3.
4.
5.
Pang W, et al. Noninvasive and real-time monitoring of Au nanoparticle promoted cancer metastasis using in vivo flow cytometry. Biomed Opt Express. 2021;12(4):1846–57.PubMedPubMedCentralCrossRef
6.
Bernacchioni C, et al. NMR metabolomics highlights sphingosine kinase-1 as a new molecular switch in the orchestration of aberrant metabolic phenotype in cancer cells. Mol Oncol. 2017;11(5):517–33.PubMedPubMedCentralCrossRef
7.
Paananen J, Fortino V. An omics perspective on drug target discovery platforms. Brief Bioinform. 2020;21(6):1937–53.PubMedCrossRef
8.
Abramczyk H, et al. Aberrant protein phosphorylation in cancer by using raman biomarkers. Cancers (Basel). 2019;11(12):2017.PubMedCrossRef
9.
10.
Soini EJO, Martikainen JA, Nousiainen T. Treatment of follicular non-Hodgkin’s lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up. Ann Oncol. 2011;22(5):1189–97.PubMedCrossRef
11.
Wu M, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.PubMedPubMedCentralCrossRef
12.
Papi A, et al. Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ. 2012;19(7):1208–19.PubMedPubMedCentralCrossRef
13.
14.
Mahajna S, et al. In vitro evaluation of chemically analyzed hypericum triquetrifolium extract efficacy in apoptosis induction and cell cycle arrest of the HCT-116 colon cancer cell line. Molecules. 2019;24(22):4139.PubMedPubMedCentralCrossRef
15.
Wassef M, Michaud A, Margueron R. Association between EZH2 expression, silencing of tumor suppressors and disease outcome in solid tumors. Cell Cycle. 2016;15(17):2256–62.PubMedPubMedCentralCrossRef
16.
17.
Dawood M, Ooko E, Efferth T. Collateral sensitivity of parthenolide via NF-κB and HIF-α inhibition and epigenetic changes in drug-resistant cancer cell lines. Front Pharmacol. 2019;10:542.PubMedPubMedCentralCrossRef
18.
Deng R, et al. BAP1 suppresses prostate cancer progression by deubiquitinating and stabilizing PTEN. Mol Oncol. 2021;15(1):279–98.PubMedCrossRef
19.
20.
Xue C, et al. The mechanism underlying the ncRNA dysregulation pattern in hepatocellular carcinoma and its tumor microenvironment. Front Immunol. 2022;13: 847728.PubMedPubMedCentralCrossRef
21.
22.
Xue C, et al. Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers. Am J Cancer Res. 2021;11(1):1–13.PubMedPubMedCentral
23.
Okazaki Y, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature. 2002;420(6915):563–73.PubMedCrossRef
24.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10(3):155–9.PubMedCrossRef
25.
26.
Aravin AA, et al. The small RNA profile during Drosophila melanogaster development. Dev Cell. 2003;5(2):337–50.PubMedCrossRef
27.
Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell. 2009;136(4):629–41.PubMedCrossRef
28.
29.
30.
Liu C, et al. NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res. 2005;33(1):D112–5.PubMed
31.
32.
Li D, et al. LncRNA, important player in bone development and disease. Endocr Metab Immune Disord Drug Targets. 2020;20(1):50–66.PubMedCrossRef
33.
34.
Yang Z, et al. LncRNA: shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev. 2019;52:17–31.PubMedCrossRef
35.
Zhu J, et al. Function of lncRNAs and approaches to lncRNA-protein interactions. Sci China Life Sci. 2013;56(10):876–85.PubMedCrossRef
36.
37.
38.
Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.PubMedCrossRef
39.
Li Y, et al. Long non-coding RNA SNHG5 promotes human hepatocellular carcinoma progression by regulating miR-26a-5p/GSK3β signal pathway. Cell Death Dis. 2018;9(9):888.PubMedPubMedCentralCrossRef
40.
Wu B, et al. Novel three-lncRNA signature predicts survival in patients with pancreatic cancer. Oncol Rep. 2018;40(6):3427–37.PubMedPubMedCentral
41.
42.
Sun CC, et al. FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway. Genome Med. 2020;12(1):77.PubMedPubMedCentralCrossRef
43.
Gao Z, et al. LncRNA MAFG-AS1 deregulated in breast cancer affects autophagy and progression of breast cancer by interacting with miR-3612 and FKBP4 invitro. Biochem Biophys Res Commun. 2022;616:95–103.PubMedCrossRef
44.
Di S, et al. Long non-coding RNA MAFG-AS1 promotes proliferation and metastasis of breast cancer by modulating STC2 pathway. Cell Death Discov. 2022;8(1):249.PubMedPubMedCentralCrossRef
45.
Dai J, et al. LncRNA MAFG-AS1 affects the tumorigenesis of breast cancer cells via the miR-574-5p/SOD2 axis. Biochem Biophys Res Commun. 2021;560:119–25.PubMedCrossRef
46.
Jia H, et al. Regulatory effect of the MAFG-AS1/miR-150-5p/MYB axis on the proliferation and migration of breast cancer cells. Int J Oncol. 2021;58(1):33–44.PubMedCrossRef
47.
Ding M, et al. Long non-coding RNA MAFG-AS1 knockdown blocks malignant progression in breast cancer cells by inactivating JAK2/STAT3 signaling pathway via MAFG-AS1/miR-3196/TFAP2A axis. Int J Clin Exp Pathol. 2020;13(10):2455–73.PubMedPubMedCentral
48.
Feng J, et al. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance. Aging (Albany NY). 2020;12(20):20658–83.PubMedCrossRef
49.
Li H, et al. LncRNA MAFG-AS1 promotes the aggressiveness of breast carcinoma through regulating miR-339-5p/MMP15. Eur Rev Med Pharmacol Sci. 2019;23(7):2838–46.PubMed
50.
Wu Q, Jiang J. LncRNA MAFG-AS1 promotes lung adenocarcinoma cell migration and invasion by targeting miR-3196 and regulating SOX12 expression. Mol Biotechnol. 2022;64(9):970–83.PubMedCrossRef
51.
Sui Y, et al. LncRNA MAFG-AS1 boosts the proliferation of lung adenocarcinoma cells via regulating miR-744-5p/MAFG axis. Eur J Pharmacol. 2019;859: 172465.PubMedCrossRef
52.
Jia YC, et al. LncRNA MAFG-AS1 facilitates the migration and invasion of NSCLC cell via sponging miR-339-5p from MMP15. Cell Biol Int. 2019;43(4):384–93.PubMedCrossRef
53.
Huang K, et al. Construction of a ceRNA network and a genomic-clinicopathologic nomogram to predict survival for HBV-related HCC. Hum Cell. 2021;34(6):1830–42.PubMedCrossRef
54.
Chen T, Huang B, Pan Y. Long NON-coding RNA MAFG-AS1 promotes cell proliferation, migration, and EMT by miR-3196/STRN4 in drug-resistant cells of liver cancer. Front Cell Dev Biol. 2021;9: 688603.PubMedPubMedCentralCrossRef
55.
Zhang F, et al. HBx-upregulated MAFG-AS1 promotes cell proliferation and migration of hepatoma cells by enhancing MAFG expression and stabilizing nonmuscle myosin IIA. Faseb j. 2021;35(5): e21529.PubMedCrossRef
56.
Hu ZQ, et al. Long noncoding RNA MAFG-AS1 facilitates the progression of hepatocellular carcinoma via targeting miR-3196/OTX1 axis. Eur Rev Med Pharmacol Sci. 2020;24(23):12131–43.PubMed
57.
Du W, et al. Identification of prognostic biomarkers of hepatocellular carcinoma via long noncoding RNA expression and copy number alterations. Epigenomics. 2020;12(15):1303–15.PubMedCrossRef
58.
Ouyang H, et al. Long noncoding RNA MAFG-AS1 promotes proliferation, migration and invasion of hepatocellular carcinoma cells through downregulation of miR-6852. Exp Ther Med. 2019;18(4):2547–53.PubMedPubMedCentral
59.
Tang C, et al. LncRNA MAFG-AS1 regulates miR-125b-5p/SphK1 axis to promote the proliferation, migration, and invasion of bladder cancer cells. Hum Cell. 2021;34(2):588–97.PubMedPubMedCentralCrossRef
60.
Xiao M, et al. MAFG-AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma. Clin Transl Med. 2020;10(8): e241.PubMedPubMedCentralCrossRef
61.
Qing L, et al. Extracellular matrix-related Six-lncRNA signature as a novel prognostic biomarker for bladder cancer. Onco Targets Ther. 2020;13:12521–38.PubMedPubMedCentralCrossRef
62.
Li D, et al. LncRNA MAFG-AS1 promotes the progression of bladder cancer by targeting the miR-143-3p/COX-2 axis. Pathobiology. 2020;87(6):345–55.PubMedCrossRef
63.
Sun X, et al. Long noncoding RNA MAFG-AS1 facilitates bladder cancer tumorigenesis via regulation of miR-143-3p/SERPINE1 axis. Transl Cancer Res. 2020;9(11):7214–26.PubMedPubMedCentralCrossRef
64.
Ruan Z, et al. Downregulation of long non-coding RNA MAFG-AS1 represses tumorigenesis of colorectal cancer cells through the microRNA-149-3p-dependent inhibition of HOXB8. Cancer Cell Int. 2020;20:511.PubMedPubMedCentralCrossRef
65.
Cui W, et al. High-expression of LncRNA MAFG-AS1 is associated with the prognostic of patients with colorectal cancer. Rev Assoc Med Bras (1992). 2020;66(11):1530–5.PubMedCrossRef
66.
Cui S, et al. LncRNA MAFG-AS1 promotes the progression of colorectal cancer by sponging miR-147b and activation of NDUFA4. Biochem Biophys Res Commun. 2018;506(1):251–8.PubMedCrossRef
67.
Fu Y, et al. LncRNA MAFG-AS1 upregulates polo-like kinase-1 by sponging miR-505 to promote gastric adenocarcinoma cell proliferation. Crit Rev Eukaryot Gene Expr. 2021;31(5):27–32.PubMedCrossRef
68.
Li C, Wu R, Xing Y. MAFG-AS1 is a novel clinical biomarker for clinical progression and unfavorable prognosis in gastric cancer. Cell Cycle. 2020;19(5):601–9.PubMedPubMedCentralCrossRef
69.
Qian CJ, et al. LncRNA MAFG-AS1 accelerates cell migration, invasion and aerobic glycolysis of esophageal squamous cell carcinoma cells via miR-765/PDX1 axis. Cancer Manag Res. 2020;12:6895–908.PubMedPubMedCentralCrossRef
70.
Wang K, et al. 5-methylcytosine RNA methyltransferases-related long non-coding RNA to develop and validate biochemical recurrence signature in prostate cancer. Front Mol Biosci. 2021;8: 775304.PubMedPubMedCentralCrossRef
71.
72.
Bai Y, et al. LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1. Cancer Gene Ther. 2022;29(3–4):277–91.PubMedCrossRef
73.
74.
75.
Wu L, et al. LncRNA TONSL-AS1 participates in coronary artery disease by interacting with miR-197. Microvasc Res. 2021;136: 104152.PubMedCrossRef
76.
Przytycki PF, Singh M. Differential allele-specific expression uncovers breast cancer genes dysregulated by Cis noncoding mutations. Cell Syst. 2020;10(2):193-203.e4.PubMedPubMedCentralCrossRef
77.
Totsuka Y, Watanabe M, Lin Y. New horizons of DNA adductome for exploring environmental causes of cancer. Cancer Sci. 2021;112(1):7–15.PubMedCrossRef
78.
Lu J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4(8): e239.PubMedPubMedCentralCrossRef
79.
Fashoyin-Aje L, et al. Integrating genetic and genomic information into effective cancer care in diverse populations. Ann Oncol. 2013;24(Suppl 7):vii48-54.PubMedPubMedCentralCrossRef
80.
Inhoffen J, et al. Deficiency of iPLA2β primes immune cells for proinflammation: potential involvement in age-related mesenteric lymph node lymphoma. Cancers (Basel). 2015;7(4):2427–42.PubMedCrossRef
81.
82.
Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992–1009.PubMedCrossRef
83.
Iuliano JN, et al. Metastatic bladder cancer cells distinctively sense and respond to physical cues of collagen fibril-mimetic nanotopography. Exp Biol Med (Maywood). 2015;240(5):601–10.PubMedCrossRef
84.
85.
86.
Zu XL, Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun. 2004;313(3):459–65.PubMedCrossRef
87.
88.
Kashima Y, et al. Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response. Sci Rep. 2018;8(1):3482.PubMedPubMedCentralCrossRef
89.
90.
Pal J, et al. Systematic analysis of migration factors by MigExpress identifies essential cell migration control genes in non-small cell lung cancer. Mol Oncol. 2021;15(7):1797–817.PubMedPubMedCentralCrossRef
91.
92.
93.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579–91.PubMedCrossRef
94.
Talagala IA, Nawarathne M, Arambepola C. Novel risk factors for primary prevention of oesophageal carcinoma: a case-control study from Sri Lanka. BMC Cancer. 2018;18(1):1135.PubMedPubMedCentralCrossRef
95.
Liu J, et al. Ginsenoside Rh2 pretreatment and withdrawal reactivated the pentose phosphate pathway to ameliorate intracellular redox disturbance and promoted intratumoral penetration of adriamycin. Redox Biol. 2020;32: 101452.PubMedPubMedCentralCrossRef
96.
Ascione CM, et al. Role of FGFR3 in bladder cancer: treatment landscape and future challenges. Cancer Treat Rev. 2023;115: 102530.PubMedCrossRef
Metadata
Title
LncRNA MAFG-AS1 is involved in human cancer progression
Authors
Penghui Li
Xiao Ma
Xinyu Gu
Publication date
01-12-2023

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Lysophospholipids and branched chain amino acids are associated with aging: a metabolomics-based study of Chinese adults

Research

Exercise and epigenetic ages in older adults with myeloid malignancies

Research

Systematic oxidative stress indices predicts prognosis in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy

Research

Association of metformin exposure with low risks of frailty and adverse outcomes in patients with diabetes

Research

The predictive value of deep learning-based cardiac ultrasound flow imaging for hypertrophic cardiomyopathy complicating arrhythmias

Research

Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous ureterostomy after radical cystectomy